{
  "pmcid": "PMC3548984",
  "pmid": "23213055",
  "title": "CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8",
  "overall_score": 0.18690876406100063,
  "num_benchmarks": 4,
  "benchmarks": {
    "drug_annotations": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 5,
        "items": [
          {
            "variant": "CYP2D6*3",
            "gene": "CYP2D6",
            "drug": "tamoxifen, anastrozole",
            "annotation": {
              "Variant/Haplotypes": "CYP2D6*3",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen, anastrozole",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "In Arm A during the first 5 years of therapy, women with 2 poor alleles had a higher likelihood of an event than women with two extensive alleles. In years 3-5, PM/PM tended towards a higher likelihood of a disease event relative to EM/EM among women on Arm A but not among women on Arm B.",
              "Sentence": "Genotype PM/PM is associated with increased odds of a disease event during tamoxifen treatment in postmenopausal women with estrogen receptor positive breast cancer.",
              "Alleles": "PM/PM",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Specialty Population": "Geriatric",
              "Population types": "in postmenopausal women",
              "Population Phenotypes or diseases": "Disease:breast cancer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05-5.73, p=0.04) had a higher likelihood of an event than women with two extensive alleles (EM/EM).",
                "In years 3-5 when patients remained on tamoxifen (Arm A), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86-6.66, p=0.09) among women on Arm A but not among women on Arm B.",
                "The negative effects of reduced CYP2D6 metabolism were observed only during the period of tamoxifen administration, and not after switching to anastrozole."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*4",
            "gene": "CYP2D6",
            "drug": "tamoxifen, anastrozole",
            "annotation": {
              "Variant/Haplotypes": "CYP2D6*4",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen, anastrozole",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "In Arm A during the first 5 years of therapy, women with 2 poor alleles had a higher likelihood of an event than women with two extensive alleles. In years 3-5, PM/PM tended towards a higher likelihood of a disease event relative to EM/EM among women on Arm A but not among women on Arm B.",
              "Sentence": "Genotype PM/PM is associated with increased odds of a disease event during tamoxifen treatment in postmenopausal women with estrogen receptor positive breast cancer.",
              "Alleles": "PM/PM",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Specialty Population": "Geriatric",
              "Population types": "in postmenopausal women",
              "Population Phenotypes or diseases": "Disease:breast cancer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05-5.73, p=0.04) had a higher likelihood of an event than women with two extensive alleles (EM/EM).",
                "In years 3-5 when patients remained on tamoxifen (Arm A), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86-6.66, p=0.09) among women on Arm A but not among women on Arm B.",
                "The negative effects of reduced CYP2D6 metabolism were observed only during the period of tamoxifen administration, and not after switching to anastrozole."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*6",
            "gene": "CYP2D6",
            "drug": "tamoxifen, anastrozole",
            "annotation": {
              "Variant/Haplotypes": "CYP2D6*6",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen, anastrozole",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "In Arm A during the first 5 years of therapy, women with 2 poor alleles had a higher likelihood of an event than women with two extensive alleles. In years 3-5, PM/PM tended towards a higher likelihood of a disease event relative to EM/EM among women on Arm A but not among women on Arm B.",
              "Sentence": "Genotype PM/PM is associated with increased odds of a disease event during tamoxifen treatment in postmenopausal women with estrogen receptor positive breast cancer.",
              "Alleles": "PM/PM",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Specialty Population": "Geriatric",
              "Population types": "in postmenopausal women",
              "Population Phenotypes or diseases": "Disease:breast cancer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05-5.73, p=0.04) had a higher likelihood of an event than women with two extensive alleles (EM/EM).",
                "In years 3-5 when patients remained on tamoxifen (Arm A), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86-6.66, p=0.09) among women on Arm A but not among women on Arm B.",
                "The negative effects of reduced CYP2D6 metabolism were observed only during the period of tamoxifen administration, and not after switching to anastrozole."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*10",
            "gene": "CYP2D6",
            "drug": "tamoxifen, anastrozole",
            "annotation": {
              "Variant/Haplotypes": "CYP2D6*10",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen, anastrozole",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "In Arm A during the first 5 years of therapy, women with 2 poor alleles had a higher likelihood of an event than women with two extensive alleles. In years 3-5, PM/PM tended towards a higher likelihood of a disease event relative to EM/EM among women on Arm A but not among women on Arm B.",
              "Sentence": "Genotype PM/PM is associated with increased odds of a disease event during tamoxifen treatment in postmenopausal women with estrogen receptor positive breast cancer.",
              "Alleles": "PM/PM",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Specialty Population": "Geriatric",
              "Population types": "in postmenopausal women",
              "Population Phenotypes or diseases": "Disease:breast cancer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05-5.73, p=0.04) had a higher likelihood of an event than women with two extensive alleles (EM/EM).",
                "In years 3-5 when patients remained on tamoxifen (Arm A), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86-6.66, p=0.09) among women on Arm A but not among women on Arm B.",
                "The negative effects of reduced CYP2D6 metabolism were observed only during the period of tamoxifen administration, and not after switching to anastrozole."
              ],
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*41",
            "gene": "CYP2D6",
            "drug": "tamoxifen, anastrozole",
            "annotation": {
              "Variant/Haplotypes": "CYP2D6*41",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen, anastrozole",
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "In Arm A during the first 5 years of therapy, women with 2 poor alleles had a higher likelihood of an event than women with two extensive alleles. In years 3-5, PM/PM tended towards a higher likelihood of a disease event relative to EM/EM among women on Arm A but not among women on Arm B.",
              "Sentence": "Genotype PM/PM is associated with increased odds of a disease event during tamoxifen treatment in postmenopausal women with estrogen receptor positive breast cancer.",
              "Alleles": "PM/PM",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Specialty Population": "Geriatric",
              "Population types": "in postmenopausal women",
              "Population Phenotypes or diseases": "Disease:breast cancer",
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05-5.73, p=0.04) had a higher likelihood of an event than women with two extensive alleles (EM/EM).",
                "In years 3-5 when patients remained on tamoxifen (Arm A), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86-6.66, p=0.09) among women on Arm A but not among women on Arm B.",
                "The negative effects of reduced CYP2D6 metabolism were observed only during the period of tamoxifen administration, and not after switching to anastrozole."
              ],
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "phenotype_annotations": {
      "score": 0.19024656265974046,
      "total_samples": 10,
      "ground_truth_annotations": {
        "count": 10,
        "matched_count": 2,
        "unmatched_count": 8,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.9618964314460754,
            "annotation": {
              "Variant/Haplotypes": "CYP2D6*1",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "Phenotype Category": "Efficacy",
              "Alleles": "*3/*3 + *4/*4",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Efficacy:Recurrence",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*1",
                "prediction": "CYP2D6",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "tamoxifen",
                "prediction": "tamoxifen",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*3/*3 + *4/*4",
                "prediction": "PM/PM, EM/EM",
                "score": 0.893781840801239,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Recurrence",
                "prediction": "disease events",
                "score": 0.848938524723053,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "EM/EM",
                "score": 0.8762439489364624,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.9618964314460754,
            "annotation": {
              "Variant/Haplotypes": "CYP2D6*4",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "Phenotype Category": "Efficacy",
              "Alleles": "*3/*3 + *4/*4",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Efficacy:Recurrence",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*4",
                "prediction": "*4",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "tamoxifen",
                "prediction": "tamoxifen",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*3/*3 + *4/*4",
                "prediction": "PM/PM, EM/EM",
                "score": 0.893781840801239,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Recurrence",
                "prediction": "disease events",
                "score": 0.848938524723053,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "EM/EM",
                "score": 0.8762439489364624,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1444933926,
              "Variant/Haplotypes": "CYP2D6*3",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "yes",
              "Notes": "Note: article did not report all genotypes; only *1/variant allele and homozygous variant allele but no combinations of variant alleles e.g. PM/IM even if phenotype grouping exist. Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *3/*3 + *4/*4 are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*3/*3 + *4/*4",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933926",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1444933959,
              "Variant/Haplotypes": "CYP2D6*1",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Note: PM/IM genotypes are missing; article did not report all genotypes; only *1/variant allele and homozygous variant allele but no combinations of variant alleles e.g. PM/IM even if phenotype grouping exist.Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*1/*3 + *1/*4 + *1/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933959",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1444933959,
              "Variant/Haplotypes": "CYP2D6*3",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Note: PM/IM genotypes are missing; article did not report all genotypes; only *1/variant allele and homozygous variant allele but no combinations of variant alleles e.g. PM/IM even if phenotype grouping exist.Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*1/*3 + *1/*4 + *1/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933959",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1444933959,
              "Variant/Haplotypes": "CYP2D6*4",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Note: PM/IM genotypes are missing; article did not report all genotypes; only *1/variant allele and homozygous variant allele but no combinations of variant alleles e.g. PM/IM even if phenotype grouping exist.Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*1/*3 + *1/*4 + *1/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933959",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1444933959,
              "Variant/Haplotypes": "CYP2D6*6",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Note: PM/IM genotypes are missing; article did not report all genotypes; only *1/variant allele and homozygous variant allele but no combinations of variant alleles e.g. PM/IM even if phenotype grouping exist.Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*1/*3 + *1/*4 + *1/*6",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933959",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1444933987,
              "Variant/Haplotypes": "CYP2D6*1",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*1/*10 + *1/*41 + *10/*10 + *41/*41",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933987",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1444933987,
              "Variant/Haplotypes": "CYP2D6*10",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*1/*10 + *1/*41 + *10/*10 + *41/*41",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933987",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1444933987,
              "Variant/Haplotypes": "CYP2D6*41",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*1/*10 + *1/*41 + *10/*10 + *41/*41",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933987",
              "_expanded_from_multi_variant": true
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 0,
        "items": []
      }
    },
    "functional_analysis": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 0,
        "items": []
      }
    },
    "study_parameters": {
      "score": 0.6491739763153924,
      "total_samples": 3,
      "ground_truth_annotations": {
        "count": 3,
        "matched_count": 3,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.6415345528546501,
            "annotation": {
              "Study Parameters ID": 1444933951,
              "Variant Annotation ID": 1444933926,
              "Study Type": "prospective",
              "Study Cases": 166.0,
              "Study Controls": 287.0,
              "Characteristics": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); PM/PM vs EM/EM",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.04",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.45,
              "Confidence Interval Start": 1.05,
              "Confidence Interval Stop": 5.73,
              "Biogeographical Groups": "European"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1444933951,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1444933926,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "prospective",
                "prediction": "case/control",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 166.0,
                "prediction": 319,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": 287.0,
                "prediction": 557,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics": {
                "ground_truth": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); PM/PM vs EM/EM",
                "prediction": "CYP2D6 genotype and treatment with tamoxifen or anastrozole in post-menopausal women with ER positive breast cancer",
                "score": 0.9060873985290527,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.04",
                "prediction": "= 0.04",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.45,
                "prediction": 2.45,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.05,
                "prediction": 1.05,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 5.73,
                "prediction": 5.73,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6415001189007479,
            "annotation": {
              "Study Parameters ID": 1444933961,
              "Variant Annotation ID": 1444933959,
              "Study Type": "prospective",
              "Study Cases": 166.0,
              "Study Controls": 287.0,
              "Characteristics": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); PM/IM and EM/PM vs EM/EM",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.07",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.67,
              "Confidence Interval Start": 0.95,
              "Confidence Interval Stop": 2.93,
              "Biogeographical Groups": "European"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1444933961,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1444933959,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "prospective",
                "prediction": "case/control",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 166.0,
                "prediction": 319,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": 287.0,
                "prediction": 557,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics": {
                "ground_truth": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); PM/IM and EM/PM vs EM/EM",
                "prediction": "CYP2D6 genotype and treatment with tamoxifen or anastrozole in post-menopausal women with ER positive breast cancer",
                "score": 0.9055020213127136,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.07",
                "prediction": "= 0.07",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 1.67,
                "prediction": 1.67,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 0.95,
                "prediction": 0.95,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 2.93,
                "prediction": 2.93,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.43536703025593476,
            "annotation": {
              "Study Parameters ID": 1444933989,
              "Variant Annotation ID": 1444933987,
              "Study Type": "prospective",
              "Study Cases": 166.0,
              "Study Controls": 287.0,
              "Characteristics": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); IM/IM and EM/IM vs EM/EM",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.6",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.23,
              "Confidence Interval Start": 0.58,
              "Confidence Interval Stop": 2.61,
              "Biogeographical Groups": "European"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1444933989,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1444933987,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "prospective",
                "prediction": "case/control",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 166.0,
                "prediction": 319,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": 287.0,
                "prediction": 557,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics": {
                "ground_truth": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); IM/IM and EM/IM vs EM/EM",
                "prediction": "CYP2D6 genotype and treatment with tamoxifen or anastrozole in post-menopausal women with ER positive breast cancer",
                "score": 0.9012395143508911,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.6",
                "prediction": "= 0.09",
                "score": 0.5,
                "match_status": "partial_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 1.23,
                "prediction": 2.4,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": 0.58,
                "prediction": 0.86,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 2.61,
                "prediction": 6.66,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European",
                "score": 1.0,
                "match_status": "match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 1,
        "items": [
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 319,
              "Study Controls": 557,
              "Characteristics": "CYP2D6 genotype and treatment with tamoxifen or anastrozole in post-menopausal women with ER positive breast cancer",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "> 0.05",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.28,
              "Confidence Interval Start": 0.03,
              "Confidence Interval Stop": 2.3,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          }
        ]
      }
    }
  }
}